Pacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $38.8 million versus the consensus estimate of $43.44 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.